Literature DB >> 11020858

Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus.

U Halm1, A Tannapfel, B Breitung, M Breidert, C W Wittekind, J Mössner.   

Abstract

BACKGROUND/AIMS: The regulation of apoptosis as a distinctive form of cell death and proliferation in the process of carcinogenesis in Barrett's esophagus is poorly understood. To investigate regulation of apoptosis, proliferation and the participation of the tumor suppressor gene p53, we examined these parameters in Barrett's metaplasia, dysplasia, and adenocarcinoma.
METHODOLOGY: Apoptotic cells were identified and quantified in tissue specimens of 45 patients with different stages of Barrett's esophagus and normal fundus epithelium, respectively, using the in situ end-labeling and electron microscopy method in combination with morphological criteria. The tumor suppressor gene p53 was examined by direct sequencing of exon 4-8 as well as immunohistochemically. The proliferative activity was assessed by Ki67 immunostaining.
RESULTS: Apoptotic cell death, identified by the in situ end-labeling and ultrastructural technique was significantly increased in Barrett's epithelium with intestinal metaplasia than in specimens with normal fundic epithelium and Barrett's carcinomas (P < 0.01). The proliferative activity, defined as Ki67 labeling index, was highest in adenocarcinomas (P < 0.01). P53 mutations were found in 8/9 adenocarcinomas and 2/5 specimens with dysplasia. Apoptosis was lower in p53 positive specimens of the metaplasia-dysplasia-carcinoma-sequence than in p53 negative specimens of Barrett's esophagus (P < 0.05).
CONCLUSIONS: The higher levels of both apoptosis and proliferation indicate an increased cell turnover in Barrett's epithelium. Apoptosis seems to maintain tissue homeostasis, which is regulated by p53, and gradually lost in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11020858

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  4 in total

1.  Evidence for DNA damage checkpoint activation in barrett esophagus.

Authors:  Urs von Holzen; Tina Chen; Amelie Boquoi; Joel E Richter; Gary W Falk; Andres J Klein-Szanto; Harry Cooper; Sam Litwin; David S Weinberg; Greg H Enders
Journal:  Transl Oncol       Date:  2010-02       Impact factor: 4.243

2.  p53 regulates Ki-67 promoter activity through p53- and Sp1-dependent manner in HeLa cells.

Authors:  Mei-Juan Wang; Dong-Sheng Pei; Guo-Wei Qian; Xiao-Xing Yin; Qian Cheng; Lian-Tao Li; Hui-Zhong Li; Jun-Nian Zheng
Journal:  Tumour Biol       Date:  2011-05-25

3.  Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study.

Authors:  Lesley A Anderson; R G Peter Watson; Seamus J Murphy; Brian T Johnston; Harry Comber; Jim Mc Guigan; John V Reynolds; Liam J Murray
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

4.  Predictable Marker for Regression of Barrett's Esophagus by Proton Pump Inhibitor Treatment in Korea.

Authors:  Hyun Jin Jo; Hye Seung Lee; Nayoung Kim; Ryoung Hee Nam; Hyun Chang; Min Soo Kim; Sung Eun Kim; Jane C Oh; Dong Ho Lee; Hyun Chae Jung
Journal:  J Neurogastroenterol Motil       Date:  2013-04-16       Impact factor: 4.924

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.